Zhejiang Kanying Import & Export Co. Ltd 86--17169758851 kanyingexport@gmail.com
C10H11N3O3S Sulfamethoxazole Powder CAS 723-46-6 Medical Grade

C10H11N3O3S Sulfamethoxazole Powder CAS 723-46-6 Medical Grade

  • High Light

    C10H11N3O3S Sulfamethoxazole Powder

    ,

    CAS 723-46-6

    ,

    Medical Grade Sulfamethoxazole

  • Product Name
    Sulfamethoxazole
  • Grade
    Meidical Grade
  • Purity
    99%
  • Color
    A Crystalline Or White Powder
  • Shelf Life
    2 Years
  • CAS No
    723-46-6
  • Storage
    Cool Dry Place
  • Brand Name
    Kan Ying
  • Place Of Origin
    India
  • Molecular Formula
    C10H11N3O3S
  • Place of Origin
    India
  • Brand Name
    Kan Ying
  • Minimum Order Quantity
    1KG
  • Price
    To discuss
  • Packaging Details
    1kg-25kg
  • Delivery Time
    2
  • Payment Terms
    L/C, D/A, D/P, T/T, Western Union, MoneyGram,Dollars
  • Supply Ability
    2000000

C10H11N3O3S Sulfamethoxazole Powder CAS 723-46-6 Medical Grade

Fight infection Sulfamethoxazole Urinary tract infection SARMS Raw Powder

 

1,  Product title:Sulfamethoxazole

 

2,  Product Description:

 

Sulfamethoxazole, the name of western medicine. Common dosage forms are tablets. For acute simple urinary tract infection caused by sensitive bacteria; When used in combination with trimethoprim, it can treat otitis media caused by sensitive Haemophilus influenzae, Streptococcus pneumoniae and other streptococcus; Astrocarniosis, etc.

 

3,  Product parameter table:

 

density

1.5±0.1 g/cm3

boiling point

482.1±55.0 °C at 760 mmHg

melting point

166 °C

Molecular formula

C10H11N3O3S

The molecular weight

253.278

point of flammability

245.4±31.5 °C

Precise quality

253.052109
PSA 106.60000
LogP 0.89

Appearance

A crystalline or white powder

vapour pressure

0.0±1.2 mmHg at 25°C

refractive index

1.641

Storage

Keep sealed, cool and dry, away from light

stability

Stable, but light sensitive. Incompatible with strong oxidizing agents.

 

 

4,  Description of necessary first aid measures:


General Advice
Consult your doctor. Show this safety technical specification to the doctor on site.
The suction
If inhaled, remove victim to fresh air. If you have stopped breathing, give mouth to mouth resuscitation. Consult your doctor.
Skin contact
Rinse with soap and plenty of water. Consult your doctor.
Eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a doctor.
eat
Never feed anything from the mouth of an unconscious person. Rinse your mouth with water. Consult your doctor.

 

5,  Adverse reactions:


1. Allergic reactions are common, which can be manifested as drug eruption. In severe cases, erythema multiforme exudative, dermatitis exfoliative and epidermolytic atrophic dermatitis bullous may occur. Also have performance for photosensitive reaction, drug heat, joint and muscle pain, fever and other serum disease like reaction.

 

2. Neutropenia or deficiency, thrombocytopenia and aplastic anemia. Patients may present with sore throat, fever, pallor, and bleeding tendencies.

 

3, hemolytic anemia and hemoglobinuria. Deficiency of glucose-6-phosphate dehydrogenase is more common in neonates and children than in adults after sulfonamides are used.

 

4. Hyperbilirubinemia and neonatal nuclear jaundice. Because sulfonamide and bilirubin compete for the protein binding site. Can cause free bilirubin heighten. Neonatal liver function is not perfect, it is easy to produce high bilirubinemia and neonatal jaundice, occasionally can produce nuclear jaundice.

 

5. Liver damage. Jaundice, liver dysfunction and acute liver necrosis may occur in severe cases.

 

6. Kidney damage. Because of the high solubility of this product in urine (free and acetylated), crystalline urine and hematuria are rare. Severe adverse reactions such as interstitial nephritis or renal tubular necrosis occurred occasionally.

 

7. Nausea, vomiting, gastric hypopnea, diarrhea, headache, fatigue, etc., the general symptoms are mild and do not affect the continued use of medication. Occasionally, patients develop C. difficile enteritis, at which point medication should be discontinued.

 

8. Goitre enlargement and hypofunction occur occasionally.

 

9. Toxic reactions of the central nervous system may occasionally occur, manifested as delirium, disorientation, hallucinations, euphoria, or depression. Once present, the drug should be discontinued immediately.

 

10. Serious adverse reactions caused by sulfonamides, though rare, can be fatal, such as erythema exudata multiforme, exfoliative dermatitis, bullae epidermolytic atrophic dermatitis, fulminant hepatic necrosis, granulocytosis, aplastic anemia and other blood system abnormalities. Treatment should be monitored closely and discontinued immediately when a rash or other early signs of reaction appear.

 

 

6,  Matters needing attention:


1. Cross allergic reaction. Patients who are allergic to one sulfonamides may also be allergic to other sulfonamides.

 

2. Liver damage. Jaundice, liver dysfunction and acute liver necrosis may occur in severe cases. Therefore, patients with liver function impairment should avoid systemic application of sulfonamides.

 

3. Kidney damage. If the application of this product course of treatment is long, large dose should be taken with sodium bicarbonate and drink more water to prevent this adverse reaction. Dehydration, shock and the use of this product in elderly patients may lead to renal damage, should be used with caution or avoid the use of this product. This product should not be used in patients with renal dysfunction.

 

4. Patients who are allergic to furosemide, sulfones, thiazide diuretics, sulfonylureas, and carbonic anhydrase inhibitors may also be allergic to sulfonamides.

 

5. Patients with lack of G-6PD and hemoporphyria should be used with caution in the following situations.

 

6, the treatment should pay attention to check:

(1) Complete blood examination is particularly important for patients who have received a longer course of treatment.

(2) Regular urine examination during treatment.

(3) Liver and kidney function examination.

 

7. Medication for pregnant and lactating women:

(1) This product can pass through the blood placenta barrier to the fetus body, animal experiments have been found to have teratogenicity. Human studies lack adequate data and should be avoided by pregnant women.

(2) This product can be secreted from the milk, the concentration in the milk can reach about 50%-100% of the maternal blood drug concentration, the drug may have an effect on the Suckling. The use of this product in neonates with glucose -6- phosphate dehydrogenase deficiency may lead to hemolytic anemia. For the above reasons, lactating women should not use this product.

 

8. Drug use for children: because sulfonamide drugs can compete with bilirubin in the binding site of plasma protein, and the acetyltransferase system of neonates is not fully developed, the free blood concentration of sulfonamide increases, thus increasing the risk of nuclear jaundice. Therefore, the use of such drugs in neonates and infants under 2 months of age is contraindicated; Because children are in the growth period, liver and kidney function is not perfect, the dosage should be reduced.

 

9. Elderly drug use: the chance of serious adverse reactions in the application of sulfonamides in elderly patients is increased. Severe skin rashes, myelosuppression and thrombocytopenia are common serious adverse reactions in the elderly. Therefore, the application should be avoided in elderly patients, and the decision should be made after weighing the advantages and disadvantages when there are definite indications.

 

10. Drug overdose: the concentration of sulfanilamide should not exceed 200mg/ml. If the concentration exceeds this, the incidence of adverse reactions will increase and the toxicity will be enhanced.

 

7,  Pictures of the product:

 

C10H11N3O3S Sulfamethoxazole Powder CAS 723-46-6 Medical Grade 0C10H11N3O3S Sulfamethoxazole Powder CAS 723-46-6 Medical Grade 1